Background: Systemic lupus erythematosus is the most severe autoimmune inflammatory diseases prototype. It is characterized by a large clinical polymorphism under the influence of genetic, immunological and environmental factors, affecting more likely women during genital activity periods. Objective: The aim of our investigation is to determine and specify the epidemiological, clinical, immunological, therapeutic and evolutionary profile of SLE in Algerian population.Patients and methods: A retrospective multicenter study was conducted on 194 lupus patients diagnosed at a higher age according to ACR and SLICC criteria, covering a period of 13 years (2006-2019). The medical records were selected from the archive data for hospital stays and by a prospective listing of patients followed in consultation.
Results:  The mean diagnosis age of our patients was (29.66±12.84). The most frequent clinical manifestations were cutaneous 71.1%, articular 74.7% and hematological 71.6%. 26.3% of the patients had nephropathies. The positive titer of antinuclear antibodies was 94.4%, anti-DNAn 66.7%, anti-Sm, RNP, SSA, and SSB in 31.5, 21, 39.5, and 19.8% of cases respectively.  The secondary anti-phospholipid syndrome was associated with 15.4% of patients. Other autoimmune diseases associated with SLE and positive family history were detected in 97.93% and 34.53% of patients respectively.  While confirming the clinical polymorphism of SLE. Conclusion: The clinical polymorphism of SLE is confirmed by our study, its severity and complexity and even the great similarities with the differences series of literature around the world, urges us to continue research to improve therapeutics for a better prognosis through early management and to enhance the life expectancy of patients.